Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2018
Pharma News, 2018
Cdc_ Flu season far from over
It’s not the worst flu season in the past decade, the Centers for Disease Control and Prevention shared during a press conference Friday morning.
Canada issues safety warning for Boehringer's Ofev after fatality
Canada’s medicines regulator has issued a safety warning related to Boehringer Ingelheim’s idiopathic pulmonary fibrosis (IPF) therapy Ofev (nintedanib).
EU approves AZ’ biologic Fasenra for severe asthma
AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.
FDA approves first treatment for breast cancer with a certain inherited genetic mutation
SILVER SPRING, Md.
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
What happenedShares of Teva Pharmaceutical Industries (NYSE.
Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.
Hung out to dry? Axovant’s terrible JPM week
SAN FRANCISCO—David Hung is the CEO who sold his company, Medivation, to Pfizer for $14 billion.
Shire’s Maribavir wins US breakthrough therapy designation
The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Shire’s investigational treatment for cytomegalovirus (CMV) infection in transplant patien...
Drug Approvals Reached Record-High In 2017
Before patients can take prescriptions to a pharmacy and get their medications, FDA has to approve drugs first.
Sanofi, Regeneron beef up investment in immunotherapies
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
Pfizer, Arvinas to collaborate on PROTACs
Arvinas and Pfizer have signed a research collaboration and license agreement relating to the discovery and development of protein degradation drug candidates.
Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs
Shire announced on Monday it would drop its revenue target of $20 billion by 2020, citing increased competition from generics and rival drug companies.
66
67
68
69
70
71
